{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:40Z","timestamp":1788498940562,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the efficacy of individualized follitropin delta dosing in patients with potential low response, defined by anti-M\u00fcllerian hormone (AMH) level &amp;lt;9 pmol\/L, undergoing ovarian stimulation for assisted reproductive technology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pooled analysis including 1844 patients from five randomized controlled trials was undertaken. The trials selected for the analysis used individualized dosing of follitropin delta, based on AMH level and body weight. Patients with potential low response (AMH screening level &amp;lt;9 pmol\/L [~1.26 ng\/mL]; n=329) were compared to patients with potential normal\/high response (AMH level \u22659 pmol\/L; n=1515). Patients with AMH &amp;lt;9 pmol\/L all received the maximum daily dose of follitropin delta (12 \u00b5g).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 34.6 years for patients with AMH &amp;lt;9 pmol\/L and 32.2 years for patients with AMH \u22659 pmol\/L, and the median AMH was 6 pmol\/L and 20 pmol\/L, respectively. In patients with AMH &amp;lt;9 pmol\/L, the mean number of oocytes retrieved (6.3 oocytes) was significantly lower (p&amp;lt;0.0001) than in patients with AMH \u22659 pmol\/L (10.8 oocytes), while no significant differences were observed for ongoing pregnancy rate (29.2% versus 31.8% in patients with AMH &amp;lt;9 pmol\/L versus \u22659 pmol\/L [p=0.32]) or live birth rate (28.6% versus 31.4% [p=0.32]). Seventeen patients (5.2%) with AMH &amp;lt;9 pmol\/L and 33 patients (2.2%) with AMH \u22659 pmol\/L had cycle cancellations due to poor response. Ovarian hyperstimulation syndrome (OHSS) occurred in 5 patients (1.5%) with AMH &amp;lt;9 pmol\/L and 112 patients (7.4%) with AMH \u22659 pmol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Follitropin delta dosing in young patients with moderately reduced ovarian reserve, using 12 \u00b5g\/day for ovarian stimulation, demonstrated clinically relevant fresh-cycle pregnancy outcomes as compared to patients with normal or high ovarian reserve. This pooled analysis adds evidence for the efficacy of follitropin delta across all ovarian reserve subgroups of the infertile population. The study was limited to fresh cycle outcomes; further studies are warranted focusing on cumulative outcomes and older patient populations with low ovarian reserve.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1880515","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:31Z","timestamp":1788495931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of follitropin delta in potential low responders: a pooled analysis of individual patient data from five randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Rita","family":"Lobo","sequence":"first","affiliation":[{"name":"Office of Chief Medical Officer, Ferring Pharmaceuticals","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Falahati","sequence":"additional","affiliation":[{"name":"Global Biometrics, Ferring Pharmaceuticals","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida E.","family":"Jepsen","sequence":"additional","affiliation":[{"name":"Office of Chief Medical Officer, Ferring Pharmaceuticals","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos P.","family":"Polyzos","sequence":"additional","affiliation":[{"name":"Dexeus Fertility, Department of Obstetrics, Gynaecology and Reproductive Medicine, Hospital Universitari Dexeus","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Garc\u00eda-Velasco","sequence":"additional","affiliation":[{"name":"IVIRMA Global Research Alliance, IVI Madrid","place":["Madrid, Spain"]},{"name":"Rey Juan Carlos University","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pinborg","sequence":"additional","affiliation":[{"name":"Fertility Clinic, Department of Gynaecology, Fertility and Obstetrics, Copenhagen University Hospital \u2013 Rigshospitalet","place":["Copenhagen, Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Medical and Health Sciences, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Gravotta","sequence":"additional","affiliation":[{"name":"Office of Chief Medical Officer, Ferring Pharmaceuticals","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B2","article-title":"Poor responders in in vitro fertilization (IVF) therapy: the challenge continues","volume":"3","author":"Oehninger","year":"2011","journal-title":"Facts Views Vis Obgyn"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey295","article-title":"Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women \u226538 years old","volume":"33","author":"Devesa","year":"2018","journal-title":"Hum Reprod"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev316","article-title":"Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos","volume":"31","author":"Drakopoulos","year":"2016","journal-title":"Hum Reprod"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2022.102307","article-title":"Association between the number of oocytes and cumulative live birth rate: A systematic review","volume":"87","author":"Neves","year":"2023","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.fertnstert.2018.04.039","article-title":"Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including \u223c15,000 women","volume":"110","author":"Polyzos","year":"2018","journal-title":"Fertil Steril"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum Reprod"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept","volume":"105","author":"Alviggi","year":"2016","journal-title":"Fertil Steril"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deu135","article-title":"Implementing the ESHRE 'poor responder' criteria in research studies: methodological implications","volume":"29","author":"Papathanasiou","year":"2014","journal-title":"Hum Reprod"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2023.05.007","article-title":"Bologna vs. POSEIDON criteria as predictors of the likelihood of obtaining at least one euploid embryo in poor ovarian response: an analysis of 6,889 cycles","volume":"120","author":"Reig","year":"2023","journal-title":"Fertil Steril"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5935\/1518-0557.20200100","article-title":"The POSEIDON stratification - moving from poor ovarian response to low prognosis","volume":"25","author":"Roque","year":"2021","journal-title":"JBRA Assist Reprod"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2023.06.028","article-title":"First Bologna, then Poseidon: What are we still missing to personalize care for patients undergoing assisted reproductive technology with a poor prognosis","volume":"120","author":"Sarkar","year":"2023","journal-title":"Fertil Steril"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-015-0595-y","article-title":"Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions","volume":"32","author":"Cohen","year":"2015","journal-title":"J Assist Reprod Genet"},{"key":"B14","unstructured":"Evaluation and management of infertility in females of advancing age\n          \n          \n            \n              Morris\n              ME\n            \n          \n          Uptodate\n          \n          2023"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00325","article-title":"Anti-mullerian hormone for the prediction of ovarian response in progestin-primed ovarian stimulation protocol for IVF","volume":"10","author":"Huang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deag018","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI: an update in 2025","volume":"24","author":"Ata","year":"2026","journal-title":"Hum Reprod"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.827678","article-title":"Editorial: Diminished ovarian reserve and poor ovarian response: diagnostic and therapeutic management","volume":"13","author":"Racca","year":"2022","journal-title":"Front Physiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1793202","article-title":"Assessment indicators of ovarian response during controlled ovarian stimulation: influencing factors and clinical value","volume":"17","author":"Xu","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum Reprod"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod BioMed Online"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2018.12.032","article-title":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles","volume":"38","author":"Fernandez-Sanchez","year":"2019","journal-title":"Reprod BioMed Online"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.08.024","article-title":"Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Mullerian hormone and body weight","volume":"43","author":"Visnova","year":"2021","journal-title":"Reprod BioMed Online"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deac061","article-title":"A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol","volume":"37","author":"Fernandez-Sanchez","year":"2022","journal-title":"Hum Reprod"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae092","article-title":"BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle","volume":"39","author":"Lobo","year":"2024","journal-title":"Hum Reprod"},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez051","article-title":"Cumulative live birth rates in low-prognosis women","volume":"34","author":"Leijdekkers","year":"2019","journal-title":"Hum Reprod"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2021.102169","article-title":"Live birth rates in different subgroups of poor ovarian responders according to Bologna and POSEIDON group classification criteria","volume":"50","author":"Mashayekhi","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2013.11.010","article-title":"Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF\/ICSI","volume":"28","author":"Polyzos","year":"2014","journal-title":"Reprod BioMed Online"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.31083\/CEOG43781","article-title":"Evaluation of the follitropin delta and clomiphene citrate combination in low prognosis women undergoing in vitro fertilization: A retrospective study","volume":"52","author":"Thi","year":"2025","journal-title":"Clin Exp Obstet Gynecol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2025.1650946","article-title":"A multicentric real-world observational study to describe the use and efficacy of follitropin delta for IVF\/ICSI procedures in patients at risk of hypo-response","volume":"7","author":"Deloire","year":"2025","journal-title":"Front Reprod Health"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoab021","article-title":"Cumulative live birth rate after IVF: trend over time and the impact of blastocyst culture and vitrification","volume":"2021","author":"Saket","year":"2021","journal-title":"Hum Reprod Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev263","article-title":"Cumulative live birth rate: time for a consensus","volume":"30","author":"Maheshrawi","year":"2015","journal-title":"Hum Reprod"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.328","article-title":"Pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line","volume":"54","author":"Olsson","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0276-8","article-title":"Dose-exposure proportionality of a novel recombinant follicle-stimulating hormone (rFSH), FE 999049, derived from a human cell line, with comparison between Caucasian and Japanese women after subcutaneous administration","volume":"35","author":"Olsson","year":"2015","journal-title":"Clin Drug Investig"},{"key":"B36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40261-022-01232-9","article-title":"Pharmacokinetics and safety of follitropin delta in gonadotropin down-regulated healthy Chinese women","volume":"43","author":"Shao","year":"2023","journal-title":"Clin Drug Investig"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1880515\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:32Z","timestamp":1788495932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1880515\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1880515"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1880515","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1880515"}}